Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma

Journal of Clinical Oncology

Volumn 33, Issue 29, 2015, Pages 3235-3242

  Gillison, Maura L ^a   Chaturvedi, Anil K ^b   Anderson, William F ^b   Fakhry, Carole ^c  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER DIAGNOSIS; CANCER SCREENING; CONTROLLED CLINICAL TRIAL (TOPIC); HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INCIDENCE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SECONDARY PREVENTION; SEXUAL BEHAVIOR; UTERINE CERVIX CANCER; WART VIRUS; CARCINOMA, SQUAMOUS CELL; COMPLICATION; HEAD AND NECK NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; VIROLOGY;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; INCIDENCE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84944238751     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.6995     Document Type: Review

References (72)

1. International Agency for Research on Cancer (ed): IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, in Human Papillomaviruses. Lyon, France, World Health Organization, 2007, p 670
2. Gillison ML, Alemany L, Snijders PJ, et al: Human papillomavirus and diseases of the upper airway: Head and neck cancer and respiratory papillomatosis. Vaccine 30: F34-F54, 2012 (suppl 5)
3. Gillison ML, Castellsagué X, Chaturvedi A, et al: Eurogin Roadmap: Comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. Int J Cancer 134: 497-507, 2014
4. Hammarstedt L, Lindquist D, Dahlstrand H, et al: Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 119: 2620-2623, 2006
5. Hong A, Lee CS, Jones D, et al: Rising prevalence of human papillomavirus related oropharyngeal cancer in Australia over the last two decades. Head Neck [epub ahead of print on December 18, 2014]
6. Forte T, Niu J, Lockwood GA, et al: Incidence trends in head and neck cancers and human papillomavirus (HPV)-associated oropharyngeal cancer in Canada, 1992-2009. Cancer Causes Control 23: 1343-1348, 2012
7. Blomberg M, Nielsen A, Munk C, et al: Trends in head and neck cancer incidence in Denmark, 1978-2007: Focus on human papillomavirus associated sites. Int J Cancer 129: 733-741, 2010
8. Reddy VM, Cundall-Curry D, Bridger MW: Trends in the incidence rates of tonsil and base of tongue cancer in England, 1985-2006. Ann R Coll Surg Engl 92: 655-659, 2010
9. Braakhuis BJ, Visser O, Leemans CR: Oral and oropharyngeal cancer in the Netherlands between 1989 and 2006: Increasing incidence, but not in young adults. Oral Oncol 45: E85-e89, 2009
10. Mork J, Møller B, Dahl T, et al: Time trends in pharyngeal cancer incidence in Norway 1981-2005: A subsite analysis based on a reabstraction and recoding of registered cases. Cancer Causes Control 21: 1397-1405, 2010
11. Jemal A, Simard EP, Dorell C, et al: Annual report to the nation on the status of cancer, 1975- 2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 105: 175-201, 2013
12. Hwang TZ, Hsiao JR, Tsai CR, et al: Incidence trends of human papillomavirus-related head and neck cancer in Taiwan, 1995-2009. Int J Cancer 137: 395-408, 2015
13. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al: Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 31: 4550-4559, 2013
14. Chaturvedi AK, Engels EA, Pfeiffer RM, et al: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29: 4294-4301, 2011
15. Hong AM, Grulich AE, Jones D, et al: Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus. Vaccine 28: 3269-3272, 2010
16. Stein AP, Saha S, Yu M, et al: Prevalence of human papillomavirus in oropharyngeal squamous cell carcinoma in the United States across time. Chem Res Toxicol 27: 462-469, 2014
17. Mehanna H, Beech T, Nicholson T, et al: The prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer: Systematic review and meta-analysis of trends by time and region. Head Neck 35: 747-755, 2013
18. Rietbergen MM, Leemans CR, Bloemena E, et al: Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm. Int J Cancer 132: 1565-1571, 2013
19. Rodrigo JP, Heideman DA, García-Pedrero JM, et al: Time trends in the prevalence of HPV in oropharyngeal squamous cell carcinomas in northern Spain (1990-2009). Int J Cancer 134: 487-492, 2014
20. Louie KS, Mehanna H, Sasieni P: Trends in head and neck cancers in England from 1995 to 2011 and projections up to 2025. Oral Oncol 51: 341- 348, 2015
21. Chaturvedi AK, Engels EA, Anderson WF, et al: Incidence trends for human papillomavirusrelated and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26: 612-619, 2008
22. US Department of Health and Human Services: Trends in Hospital Utilization: United States, 1965-1986, in National Center for Health Statistics. Hyattsville, MD, Department of Health and Human Services Publication, 1989
23. Fakhry C, Andersen K, Christensen J, et al: The impact of tonsillectomy upon the risk of oropharyngeal carcinoma diagnosis and prognosis in the Danish Cancer Registry. Cancer Prev Res (Phila) [epub ahead of print on April 20, 2015]
24. Chaturvedi A: Tonsillectomy and risk of oropharyngeal cancer. Cancer Prev Res (Phila) [epub ahead of print on April 20, 2015]
25. Abogunrin S, Di Tanna GL, Keeping S, et al: Prevalence of human papillomavirus in head and neck cancers in European populations: A metaanalysis. BMC Cancer 14: 968, 2014
26. Ndiaye C, Mena M, Alemany L, et al: HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: A systematic review and metaanalysis. Lancet Oncol 15: 1319-1331, 2014
27. Combes JD, Franceschi S: Role of human papillomavirus in non-oropharyngeal head and neck cancers. Oral Oncol 50: 370-379, 2014
28. Castellsague X, Alemany L, Holzinger D, et al: Estimation of the HPV etiological fraction in over 4,000 head and neck cancers worldwide. Presented at the International Human Papillomavirus Conference, Seattle, WA, August 24, 2014
29. Gillison ML, Broutian T, Pickard RK, et al: Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 307: 693-703, 2012
30. Lingen MW, Xiao W, Schmitt A, et al: Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol 49: 1-8, 2013
31. Torre LA, Bray F, Siegel RL, et al: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015
32. de Martel C, Ferlay J, Franceschi S, et al: The global burden of cancers attributable to infections in the year 2008: A review and synthetic analysis. Lancet Oncol 13: 607-615, 2012
33. Steinau M, Saraiya M, Goodman MT, et al: Human papillomavirus prevalence in oropharyngeal cancer before vaccine introduction, United States. Emerg Infect Dis 20: 822-828, 2014
34. Gillison ML, D'Souza G, Westra W, et al: Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100: 407-420, 2008
35. Ng M, Freeman MK, Fleming TD, et al: Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA 311: 183-192, 2014
36. Heck JE, Berthiller J, Vaccarella S, et al: Sexual behaviours and the risk of head and neck cancers: A pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol 39: 166-181, 2010
37. Prendes BL, Wang SJ, Groppo ER, et al: Oral human papillomavirus infection in men who have sex with men with anal squamous intraepithelial lesions. Head Neck [epub ahead of print on January 12, 2015]
38. Beachler DC, Weber KM, Margolick JB, et al: Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults. Cancer Epidemiol Biomarkers Prev 21: 122-133, 2012
39. D'Souza G, Kluz N, Wentz A, et al: Oral human papillomavirus (HPV) infection among unvaccinated high-risk young adults. Cancers (Basel) 6: 1691-1704, 2014
40. Dahlstrom KR, Burchell AN, Ramanakumar AV, et al: Sexual transmission of oral human papillomavirus infection among men. Cancer Epidemiol Biomarkers Prev 23: 2959-2964, 2014
41. Lang Kuhs KA, Gonzalez P, Struijk L, et al: Prevalence of and risk factors for oral human papillomavirus among young women in Costa Rica. J Infect Dis 208: 1643-1652, 2013
42. Mbulawa ZZ, Johnson LF, Marais DJ, et al: Risk factors for oral human papillomavirus in heterosexual couples in an African setting. J Infect 68: 185-189, 2014
43. Vogt SL, Gravitt PE, Martinson NA, et al: Concordant oral-genital HPV infection in South Africa couples: Evidence for transmission. Front Oncol 3: 303, 2013
44. Beachler DC, Sugar EA, Margolick JB, et al: Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults. Am J Epidemiol 181: 40-53, 2015
45. Edelstein ZR, Schwartz SM, Hawes S, et al: Rates and determinants of oral human papillomavirus infection in young men. Sex Transm Dis 39: 860-867, 2012
46. Pickard R, Xiao W, Broutian T, et al: The prevalence and incidence of oral human papillomavirus infection among young men and women, age 18-30 years. Sex Transm Dis 39: 559-566, 2012
47. Kreimer AR, Pierce Campbell CM, Lin HY, et al: Incidence and clearance of oral human papillomavirus infection in men: The HIM cohort study. Lancet 382: 877-887, 2013
48. D'Souza G, Cullen K, Bowie J, et al: Differences in oral sexual behaviors by gender, age, and race explain observed differences in prevalence of oral human papillomavirus infection. PLoS One 9: E86023, 2014
49. Chaturvedi A, Graubard B, Broutian T, et al: NHANES 2009-2012 findings: Association of sexual behaviors with higher prevalence of oral oncogenic human papillomavirus infections in U.S. men. Cancer Res [epub ahead of print on April 14, 2015]
50. Giuliano AR, Nyitray AG, Kreimer AR, et al: EUROGIN 2014 roadmap: Differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer 136: 2752-2760, 2015
51. Ho GY, Studentsov Y, Hall CB, et al: Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 186: 737-742, 2002
52. Safaeian M, Porras C, Schiffman M, et al: Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 102: 1653-1662, 2010
53. Wilson L, Pawlita M, Castle PE, et al: Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection. J Infect Dis 210: 448-455, 2014
54. Schiffman M, Solomon D: Clinical practice: Cervical-cancer screening with human papillomavirus and cytologic cotesting. N Engl J Med 369: 2324-2331, 2013
55. Lehtinen M, Dillner J: Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol 10: 400-410, 2013
56. Jit M, Brisson M, Portnoy A, et al: Costeffectiveness of female human papillomavirus vaccination in 179 countries: A PRIME modelling study. Lancet Glob Health 2: E406-e414, 2014
57. International Agency for Research on Cancer (ed): Primary end-points for prophylactic HPV vaccine trials, in IARC Working Group Reports. Geneva, Switzerland, World Health Organization, 2014, pp 1-104
58. Herrero R, Quint W, Hildesheim A, et al: Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One 8: E68329, 2013
59. Fakhry C, Agrawal N, Califano J, et al: The use of ultrasound in the search for the primary site of unknown primary head and neck squamous cell cancers. Oral Oncol 50: 640-645, 2014
60. Blanco RG, Califano J, Messing B, et al: Transcervical ultrasonography is feasible to visualize and evaluate base of tongue cancers. PLoS One 9: E87565, 2014
61. Fakhry C, Rosenthal BT, Clark DP, et al: Associations between oral HPV16 infection and cytopathology: Evaluation of an oropharyngeal "pap-test equivalent" in high-risk populations. Cancer Prev Res (Phila) 4: 1378-1384, 2011
62. Castle PE: Teaching moment: Why promising biomarkers do not always translate into clinically useful tests. J Clin Oncol 32: 359-361, 2014
63. D'Souza G, Gross ND, Pai SI, et al: Oral human papillomavirus (HPV) infection in HPVpositive patients with oropharyngeal cancer and their partners. J Clin Oncol 32: 2408-2415, 2014
64. Ahn SM, Chan JY, Zhang Z, et al: Saliva and plasma quantitative polymerase chain reactionbased detection and surveillance of human papillomavirus-related head and neck cancer. JAMA Otolaryngol Head Neck Surg 140: 846-854, 2014
65. Nordfors C, Vlastos A, Du J, et al: Human papillomavirus prevalence is high in oral samples of patients with tonsillar and base of tongue cancer. Oral Oncol 50: 491-497, 2014
66. Anantharaman D, Gheit T, Waterboer T, et al: Human papillomavirus infections and upper aerodigestive tract cancers: The ARCAGE study. J Natl Cancer Inst 105: 536-545, 2013
67. D'Souza G, Kreimer AR, Viscidi R, et al: Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356: 1944- 1956, 2007
68. Koslabova E, Hamsikova E, Salakova M, et al: Markers of HPV infection and survival in patients with head and neck tumors. Int J Cancer 133: 1832- 1839, 2013
69. Liang C, Marsit CJ, McClean MD, et al: Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res 72: 5004-5013, 2012
70. Kreimer AR, Johansson M, Waterboer T, et al: Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol 31: 2708-2715, 2013
71. Chen HC, Schiffman M, Lin CY, et al: Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst 103: 1387-1396, 2011
72. Lang Kuhs KA, Anantharaman D, Waterboer T, et al: Human papillomavirus 16 E6 antibodies in individuals without diagnosed cancer: A pooled analysis. Cancer Epidemiol Biomarkers Prev 24: 683-689, 2015